menu
    • menu
    [{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Glimepiride","moa":"||SUR 1\/Kir6.2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Inapplicable"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Termination","leadProduct":"Dapagliflozin Propanediol Monohydrate","moa":"||SGLT2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Abbott Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Abbott Laboratories \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Abbott Laboratories \/ AstraZeneca"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Dapagliflozin Propanediol Monohydrate","moa":"SGLT2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Sun Pharmaceutical Industries Limited"}]

    Find Clinical Drug Pipeline Developments & Deals for Dapagliflozin Propanediol

    Menu

    Dapagliflozin Propanediol

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    MARKET PLACE

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Sun Pharmaceutical Industries Limited

    India arrow
    Peptide Therapy Summit
    Not Confirmed

    Sun Pharmaceutical Industries Limited

    India arrow
    Peptide Therapy Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Glimepiride,Dapagliflozin Propanediol Monohydrate

    Therapeutic Area : Endocrinology

    Study Phase : Approved FDF

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Sun Pharma Dapagliflozin Glimepiride Metformin FDC gets CDSCO Panel Nod for Phase 3 Trial

    Details : Dapagliflozin, metformin and glimepiride fixed dose combination is approved for the treatment of patients with type 2 diabetes.

    Product Name : Gemer Dapa

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    November 24, 2021

    Lead Product(s) : Glimepiride,Dapagliflozin Propanediol Monohydrate

    Therapeutic Area : Endocrinology

    Highest Development Status : Approved FDF

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    Abbott Laboratories

    U.S.A arrow
    Peptide Therapy Summit
    Not Confirmed

    Abbott Laboratories

    U.S.A arrow
    Peptide Therapy Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Dapagliflozin Propanediol Monohydrate,Metformin

    Therapeutic Area : Endocrinology

    Study Phase : Approved FDF

    Sponsor : AstraZeneca

    Deal Size : Undisclosed

    Deal Type : Termination

    DEALS_DEV arrow-down

    AstraZeneca Pharma, Abbott Healthcare Terminate Distribution Agreements for Diabetes Drug in India

    Details : After termination of the agreement, AstraZeneca India will continue to independently market Dapagliflozin, the combinations of Dapagliflozin and Metformin as well as Dapagliflozin and Saxagliptin in India under the brand names Forxiga, Xigduo and Qtern r...

    Product Name : Xigduo

    Product Type : Other Small Molecule

    Upfront Cash : Undisclosed

    May 28, 2021

    Lead Product(s) : Dapagliflozin Propanediol Monohydrate,Metformin

    Therapeutic Area : Endocrinology

    Highest Development Status : Approved FDF

    Sponsor : AstraZeneca

    Deal Size : Undisclosed

    Deal Type : Termination

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    AstraZeneca

    United Kingdom arrow
    Peptide Therapy Summit
    Not Confirmed

    AstraZeneca

    United Kingdom arrow
    Peptide Therapy Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Dapagliflozin Propanediol Monohydrate

    Therapeutic Area : Endocrinology

    Study Phase : Approved FDF

    Sponsor : Sun Pharmaceutical Industries Limited

    Deal Size : Undisclosed

    Deal Type : Acquisition

    DEALS_DEV arrow-down

    Sun Pharma Acquires Rights to Trademarks of Three Diabetes Drug Brands in India from AstraZeneca

    Details : AstraZeneca India has granted rights to Sun Pharma to promote and distribute Dapagliflozin under the brand name Oxra. Sun Pharma also gained the rights to promote and distribute the Oxramet (Dapagliflozin + Metformin) and Oxraduo (Dapagliflozin + Saxagli...

    Product Name : Oxra

    Product Type : Other Small Molecule

    Upfront Cash : Undisclosed

    May 28, 2021

    Lead Product(s) : Dapagliflozin Propanediol Monohydrate

    Therapeutic Area : Endocrinology

    Highest Development Status : Approved FDF

    Sponsor : Sun Pharmaceutical Industries Limited

    Deal Size : Undisclosed

    Deal Type : Acquisition

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth